The TACSI trial compared dual antiplatelet therapy (DAPT) with aspirin and ticagrelor for 12 months versus aspirin alone in patients with acute coronary syndrome after coronary artery bypass graft (CABG) surgery.[2][3][4] It included 2201 patients with a mean age of 66 years, of whom 14.4% were women, with a 12-month follow-up.[4] The primary endpoint—a composite of death from any cause, myocardial infarction, stroke, or new coronary revascularization—achieved nearly 5% in both groups with no difference.[2][3][4] DAPT did not improve the prevention of cardiovascular events over aspirin alone.[2][3] Conversely, the incidence of major bleeding increased with DAPT.[2][3][4] The results suggest that current recommendations for DAPT after CABG in patients with acute coronary syndrome should be changed in favor of aspirin alone.[3][4]